X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aurobindo Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
ADCOCK INGRAM
Jun-14
AUROBINDO PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs895404-   
Low Rs622291-   
Sales per share (Unadj.) Rs254.6120.1-  
Earnings per share (Unadj.) Rs39.3-30.3-  
Cash flow per share (Unadj.) Rs46.6-25.1-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs160.094.3-  
Shares outstanding (eoy) m585.88168.78-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.9 103.0%   
Avg P/E ratio x19.3-11.5 -168.2%  
P/CF ratio (eoy) x16.3-13.9 -117.5%  
Price / Book Value ratio x4.73.7 128.6%  
Dividend payout %6.40-   
Avg Mkt Cap Rs m444,39058,663 757.5%   
No. of employees `00014.04.3 325.7%   
Total wages/salary Rs m17,6783,682 480.1%   
Avg. sales/employee Rs Th10,667.84,722.8 225.9%   
Avg. wages/employee Rs Th1,264.3857.6 147.4%   
Avg. net profit/employee Rs Th1,645.8-1,190.0 -138.3%   
INCOME DATA
Net Sales Rs m149,15720,275 735.7%  
Other income Rs m1,159142 816.2%   
Total revenues Rs m150,31620,417 736.2%   
Gross profit Rs m34,343-3,514 -977.5%  
Depreciation Rs m4,276875 488.7%   
Interest Rs m667549 121.5%   
Profit before tax Rs m30,558-4,796 -637.2%   
Minority Interest Rs m50-13 -375.5%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,597300 2,535.0%   
Profit after tax Rs m23,012-5,109 -450.4%  
Gross profit margin %23.0-17.3 -132.9%  
Effective tax rate %24.9-6.2 -397.8%   
Net profit margin %15.4-25.2 -61.2%  
BALANCE SHEET DATA
Current assets Rs m92,06214,850 620.0%   
Current liabilities Rs m66,2238,355 792.6%   
Net working cap to sales %17.332.0 54.1%  
Current ratio x1.41.8 78.2%  
Inventory Days Days106111 95.6%  
Debtors Days Days68124 54.6%  
Net fixed assets Rs m62,9198,656 726.9%   
Share capital Rs m58694 622.4%   
"Free" reserves Rs m93,1330-   
Net worth Rs m93,71915,913 588.9%   
Long term debt Rs m1,8145,592 32.4%   
Total assets Rs m162,49430,062 540.5%  
Interest coverage x46.8-7.7 -605.3%   
Debt to equity ratio x00.4 5.5%  
Sales to assets ratio x0.90.7 136.1%   
Return on assets %14.6-15.2 -96.1%  
Return on equity %24.6-32.1 -76.5%  
Return on capital %32.7-19.8 -165.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m45,6130-   
CASH FLOW
From Operations Rs m32,7861,731 1,894.5%  
From Investments Rs m-17,870-531 3,363.0%  
From Financial Activity Rs m-19,1535,075 -377.4%  
Net Cashflow Rs m-4,2396,275 -67.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.57 Rs / ZAR

Compare AUROBINDO PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: PLETHICO PHARMA  ABBOTT INDIA  FULFORD INDIA  ORCHID PHARMA LTD  SUVEN LIFE  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - TORRENT PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS